vs

Side-by-side financial comparison of Roivant Sciences Ltd. (ROIV) and XCel Brands, Inc. (XELB). Click either name above to swap in a different company.

Roivant Sciences Ltd. is the larger business by last-quarter revenue ($2.0M vs $1.2M, roughly 1.7× XCel Brands, Inc.). XCel Brands, Inc. runs the higher net margin — -237.8% vs -13301.2%, a 13063.4% gap on every dollar of revenue. On growth, XCel Brands, Inc. posted the faster year-over-year revenue change (-3.4% vs -77.8%). XCel Brands, Inc. produced more free cash flow last quarter ($-7.0M vs $-201.4M). Over the past eight quarters, XCel Brands, Inc.'s revenue compounded faster (-26.9% CAGR vs -73.7%).

Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel.

XCel Brands, Inc. is a consumer goods and brand management firm that owns, licenses, and markets lifestyle brands spanning apparel, accessories, and home products. It operates mainly in North America, partnering with leading retail chains to distribute products to mass and mid-tier consumer segments.

ROIV vs XELB — Head-to-Head

Bigger by revenue
ROIV
ROIV
1.7× larger
ROIV
$2.0M
$1.2M
XELB
Growing faster (revenue YoY)
XELB
XELB
+74.4% gap
XELB
-3.4%
-77.8%
ROIV
Higher net margin
XELB
XELB
13063.4% more per $
XELB
-237.8%
-13301.2%
ROIV
More free cash flow
XELB
XELB
$194.4M more FCF
XELB
$-7.0M
$-201.4M
ROIV
Faster 2-yr revenue CAGR
XELB
XELB
Annualised
XELB
-26.9%
-73.7%
ROIV

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
ROIV
ROIV
XELB
XELB
Revenue
$2.0M
$1.2M
Net Profit
$-265.9M
$-2.8M
Gross Margin
Operating Margin
-16966.1%
-166.8%
Net Margin
-13301.2%
-237.8%
Revenue YoY
-77.8%
-3.4%
Net Profit YoY
-257.0%
60.8%
EPS (diluted)
$-0.38
$-0.22

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ROIV
ROIV
XELB
XELB
Q4 25
$2.0M
$1.2M
Q3 25
$1.6M
$1.1M
Q2 25
$2.2M
$1.3M
Q1 25
$-39.6M
$1.3M
Q4 24
$9.0M
$1.2M
Q3 24
$4.5M
$1.9M
Q2 24
$8.0M
$3.0M
Q1 24
$28.9M
$2.2M
Net Profit
ROIV
ROIV
XELB
XELB
Q4 25
$-265.9M
$-2.8M
Q3 25
$-113.5M
$-7.9M
Q2 25
$-223.4M
$-4.0M
Q1 25
$-206.5M
$-2.8M
Q4 24
$169.4M
$-7.1M
Q3 24
$-230.2M
$-9.2M
Q2 24
$95.3M
$195.0K
Q1 24
$-151.1M
$-6.3M
Gross Margin
ROIV
ROIV
XELB
XELB
Q4 25
Q3 25
100.0%
Q2 25
100.0%
Q1 25
Q4 24
100.0%
Q3 24
78.7%
Q2 24
98.7%
Q1 24
100.0%
Operating Margin
ROIV
ROIV
XELB
XELB
Q4 25
-16966.1%
-166.8%
Q3 25
-19492.9%
-665.7%
Q2 25
-13130.0%
-125.2%
Q1 25
674.8%
-164.2%
Q4 24
-3042.6%
-532.9%
Q3 24
-7636.0%
-474.8%
Q2 24
-1279.5%
10.4%
Q1 24
-919.5%
-283.7%
Net Margin
ROIV
ROIV
XELB
XELB
Q4 25
-13301.2%
-237.8%
Q3 25
-7225.9%
-706.5%
Q2 25
-10292.9%
-301.9%
Q1 25
521.8%
-210.0%
Q4 24
1878.3%
-585.9%
Q3 24
-5143.8%
-481.9%
Q2 24
1192.7%
6.6%
Q1 24
-522.3%
-288.2%
EPS (diluted)
ROIV
ROIV
XELB
XELB
Q4 25
$-0.38
$-0.22
Q3 25
$-0.17
$-2.02
Q2 25
$-0.33
$-1.66
Q1 25
$-0.28
$-1.18
Q4 24
$0.23
$-2.91
Q3 24
$-0.31
$-3.92
Q2 24
$0.12
$0.08
Q1 24
$-0.02
$-3.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ROIV
ROIV
XELB
XELB
Cash + ST InvestmentsLiquidity on hand
$4.5B
$1.1M
Total DebtLower is stronger
$12.7M
Stockholders' EquityBook value
$4.3B
$18.0M
Total Assets
$5.2B
$38.9M
Debt / EquityLower = less leverage
0.71×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ROIV
ROIV
XELB
XELB
Q4 25
$4.5B
$1.1M
Q3 25
$4.4B
$1.5M
Q2 25
$4.5B
$970.0K
Q1 25
$4.9B
$298.0K
Q4 24
$5.1B
$1.3M
Q3 24
$5.4B
$242.0K
Q2 24
$5.7B
$924.0K
Q1 24
$6.5B
$1.6M
Total Debt
ROIV
ROIV
XELB
XELB
Q4 25
$12.7M
Q3 25
$12.5M
Q2 25
$12.3M
Q1 25
$8.7M
Q4 24
$6.6M
Q3 24
$4.3M
Q2 24
$311.7M
$4.5M
Q1 24
$430.6M
$4.7M
Stockholders' Equity
ROIV
ROIV
XELB
XELB
Q4 25
$4.3B
$18.0M
Q3 25
$4.4B
$18.7M
Q2 25
$4.3B
$24.5M
Q1 25
$4.7B
$27.7M
Q4 24
$5.2B
$30.4M
Q3 24
$5.2B
$36.9M
Q2 24
$5.4B
$46.0M
Q1 24
$6.0B
$45.8M
Total Assets
ROIV
ROIV
XELB
XELB
Q4 25
$5.2B
$38.9M
Q3 25
$5.1B
$40.5M
Q2 25
$5.0B
$47.2M
Q1 25
$5.4B
$52.5M
Q4 24
$5.8B
$53.8M
Q3 24
$6.2B
$54.0M
Q2 24
$6.5B
$63.2M
Q1 24
$7.2B
$66.8M
Debt / Equity
ROIV
ROIV
XELB
XELB
Q4 25
0.71×
Q3 25
0.67×
Q2 25
0.50×
Q1 25
0.31×
Q4 24
0.22×
Q3 24
0.12×
Q2 24
0.06×
0.10×
Q1 24
0.07×
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ROIV
ROIV
XELB
XELB
Operating Cash FlowLast quarter
$-196.5M
$-7.0M
Free Cash FlowOCF − Capex
$-201.4M
$-7.0M
FCF MarginFCF / Revenue
-10076.0%
-602.1%
Capex IntensityCapex / Revenue
246.9%
0.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-776.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ROIV
ROIV
XELB
XELB
Q4 25
$-196.5M
$-7.0M
Q3 25
$-185.7M
$-1.4M
Q2 25
$-204.4M
$-2.4M
Q1 25
$-172.6M
$-1.4M
Q4 24
$-207.3M
$-4.7M
Q3 24
$-266.8M
$-424.0K
Q2 24
$-192.8M
$-274.0K
Q1 24
$-108.5M
$-2.6M
Free Cash Flow
ROIV
ROIV
XELB
XELB
Q4 25
$-201.4M
$-7.0M
Q3 25
$-193.5M
Q2 25
$-208.4M
$-2.4M
Q1 25
$-173.4M
$-1.4M
Q4 24
$-209.1M
$-4.8M
Q3 24
$-267.8M
$-432.0K
Q2 24
$-193.8M
Q1 24
$-108.8M
FCF Margin
ROIV
ROIV
XELB
XELB
Q4 25
-10076.0%
-602.1%
Q3 25
-12317.8%
Q2 25
-9604.5%
-179.3%
Q1 25
438.1%
-108.7%
Q4 24
-2318.5%
-399.3%
Q3 24
-5984.4%
-22.6%
Q2 24
-2425.5%
Q1 24
-376.1%
Capex Intensity
ROIV
ROIV
XELB
XELB
Q4 25
246.9%
0.9%
Q3 25
499.6%
0.0%
Q2 25
185.9%
0.3%
Q1 25
-2.0%
1.1%
Q4 24
20.3%
9.3%
Q3 24
22.3%
0.4%
Q2 24
12.1%
Q1 24
1.2%
Cash Conversion
ROIV
ROIV
XELB
XELB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-1.22×
Q3 24
Q2 24
-2.02×
-1.41×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons